



RESEARCH2REALITY

Shining a light on research & innovation.

Reaching the 'Common Goal' of Improving Human Health

An interview with **Population Health Research Institute** researchers:

Salim Yusuf, Cardiologist, Executive Director

Jackie Bosch, Occupational Therapist

and **Bayer Inc.** researchers:

Shurjeel Choudhri, Senior VP — Medical & Scientific Affairs

Chrisoula Giannaris, Head, Medical Affairs — Hematology, Oncology & Radiology

Antonio Ciaccia, Head, Medical Affairs — Cardiology, Nephrology & Respiriology

Laurie Wingett, Head, Medical Affairs — Primary Care & Medical Operations

Salim Yusuf

For many decades, we put a number of pharmaceutical companies on individual projects, and usually they were testing the value of various treatments or preventative strategies. We did the same thing in a number of projects with Bayer, but we found we had much more in common, and so we struck a partnership.

Shurjeel Choudhri

As a company, we look at diseases where either there is no treatment, or there are treatment options that are not very good or have too many side effects, and we're trying to address that unmet need.

TODAY'S RESEARCH. TOMORROW'S REALITY.



Jackie Bosch

Collaboration with industry has allowed Canada to become a powerhouse in clinical trials research. It enabled us to be able to do the studies that we thought were really important. And the interesting thing about industry collaboration is it often is a risk for industry. We do studies on compounds that you know work in certain people. We want to expand that use. We think it could be beneficial to more people. And that often takes risk, because if this study doesn't come out positive, that company that owns that drug, it could be to their detriment to have these answers.

Chrisoula Giannaris

Working with physicians in Canada to bring forward some of their research projects, and collaborate with them with Bayer, that's when it really creates value for Canadians.

Salim Yusuf

We're interested, as a research group, in making a human impact. So we have basic discovery level work, and ultimately translating that into practice that will improve patient outcomes.

Antonio Ciaccia

We're really looking to better understand the mechanism of disease, and this will hopefully help in the future, whether it's in academia or in industry



through biotechnology companies or through pharmaceutical companies like Bayer.

Laurie Wingett

We have a common goal, and on the academia side, they have the strength of the knowledge and the research. On the pharmaceutical side, we tend to dig a little bit deeper into the therapeutic areas. And when we come together, we're able to reach that common goal.

Shurjeel Choudhri

Science is moving very quickly, and no one company or organization can really do it all. And that's really what the future will look like. It will be very much a collaborative effort.